Latest Headlines

Latest Headlines

Amid ongoing restructuring and layoffs at Siemens, healthcare leads

Healthcare was one of the strongest segments at German conglomerate Siemens last quarter, both in terms of sales growth and profitability. That could help insulate this business, comprised mostly of imaging and diagnostics, from an ongoing restructuring that aims to trim employees and costs from its worst performing businesses.

AZ, GSK ink academic hookup; EU blasts past 2014 fundraising haul; Erytech plans U.S. IPO

In this week's EuroBiotech Report, data from market analyst Biocom shows that biotechs traded in Europe raised €3 billion ($3.3 billion) in the first half of the year, more than they gathered in all of 2014. AC Immune and Erytech could contribute to the back half of 2015 being an equally busy period. And more.

AstraZeneca, GSK snag a direct line to researchers at Cambridge academic hub

AstraZeneca and GlaxoSmithKline have secured direct connections to researchers at the University of Cambridge and its associated academic institutions. The arrangement is part of a "matchmaking" scheme, in which drugmakers will provide academics with funding for collaborative research and access to their experimental therapies.

Startup raises $35M to back first FDA-approved dermal filler for acne scars

Innovations in aesthetic medicine have proven lucrative in the medical device industry, given a growing and aging population with disposable income. Investors are betting that a dermal filler to treat acne scars--that's the first approved by the FDA--could be the next ticket to successful commercialization in aesthetics.

Erytech pushes ahead with plan to file IPO on Nasdaq to fund cancer pipeline

Erytech is poised to become the latest in a long line of European biotechs to head to Wall Street in search of cash. The proposal marks an escalation of the cancer biotech's long-running flirtation with U.S. investors, which has already seen it set up on the OTC market and tap stateside sources for its previous fundraising round.

Europe's public biotechs blast past 2014 fundraising total in just 6 months

Biotechs listed on European stock exchanges have raised more money in the first half of 2015 than in all of last year, according to a report by Biocom. Over the first 6 months of 2015, €3 billion ($3.3 billion) flowed into Europe's 161 listed biotechs, one-quarter more than they added to their coffers in all of 2014.

Roche's persistence in Alzheimer's moves AC Immune a step closer to an IPO

Roche's willingness to continue plugging away with Alzheimer's programs despite setbacks has moved AC Immune a step closer to filing for an IPO. The Big Pharma has decided to advance the Alzheimer's treatment it licensed from AC Immune into Phase III, giving its partner the confidence to consider tapping public markets for cash.

Sprint licenses tumor metabolism program to Bayer in €190M deal

Sprint Bioscience (STO:SPRINT) has entered into a cancer research collaboration with Bayer, handing over the rights to an early-stage tumor metabolism program in return for €190 million ($210 million) in upfront and milestone payments.

Ablynx inks €4B Merck I-O deal; Big hitters give KalVista $33M; Israeli biotechs grab $209M

In this week's EuroBiotech Report, Ablynx expanded its immuno-oncology pact with Merck. If everything comes off, Ablynx will find itself €4 billion richer. The snag? Almost all of the money is tied to milestones, with Merck handing over just €13 million upfront. And more.

KalVista snags $33M from big-name VCs to speed plasma kallikrein inhibitors into clinic

KalVista Pharmaceuticals has persuaded Novo A/S, SV Life Sciences and some other notable VCs to part with $33 million (€29 million). The cash will go toward advancing KalVista's pipeline of plasma kallikrein inhibitors, the most advanced of which is set to enter Phase II next year.